Co-Mn Complex Oxide Nanoparticles As Potential Reactive Oxygen Species Scavenging Agents for Pulmonary Fibrosis Treatment

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Nov 9

PMID 39519747

Authors

Wuhao Yang

Hui Yuan

Hao Sun

Ting Hu

Yaping Xu

Yan Qiu

Yuhang Li

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and age-related lung disease that has few treatment options. Reactive oxygen species (ROS) play an important role in the introduction and development of IPF. In the present study, we developed multifunctional Cobalt (Co)-Manganese (Mn) complex oxide nanoparticles (Co-MnNPs), which can scavenge multiple types of ROS. Benefiting from ROS scavenging activities and good biosafety, Co-MnNPs can suppress canonical and non-canonical TGF-β pathways and, thus, inhibit the activation of fibroblasts and the productions of extracellular matrix. Furthermore, the scavenging of ROS by Co-MnNPs reduce the LPS-induced expressions of pro-inflammatory factors in macrophages, by suppressing NF-κB signaling pathway. Therefore, Co-MnNPs can reduce the excessive extracellular matrix deposition and inflammatory responses in lungs and, thus, alleviate pulmonary fibrosis induced by bleomycin (BLM) in mice. Taken together, this work offers an anti-fibrotic agent for treatment of IPF and other ROS-related diseases.

References

Wollin L, Distler J, Redente E, Riches D, Stowasser S, Schlenker-Herceg R . Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019; 54(3). PMC: 6751387. DOI: 10.1183/13993003.00161-2019. View

Zhao J, Gao W, Cai X, Xu J, Zou D, Li Z . Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics. 2019; 9(10):2843-2855. PMC: 6568174. DOI: 10.7150/thno.33727. View

Dsouza N, Alampady V, Baby K, Maity S, Byregowda B, Nayak Y . Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. Inflammopharmacology. 2023; 31(3):1167-1182. PMC: 10039777. DOI: 10.1007/s10787-023-01193-1. View

Li M, Zhou Y, Wang T, Li M, Chen X, Zhang T . Nintedanib exerts anti-pulmonary fibrosis activity inhibiting TANK-binding kinase 1 (TBK1) phosphorylation. Chem Commun (Camb). 2022; 58(8):1199-1202. DOI: 10.1039/d1cc05621b. View

Wu K, Xiu Y, Zhou P, Qiu Y, Li Y . A New Use for an Old Drug: Carmofur Attenuates Lipopolysaccharide (LPS)-Induced Acute Lung Injury Inhibition of FAAH and NAAA Activities. Front Pharmacol. 2019; 10:818. PMC: 6659393. DOI: 10.3389/fphar.2019.00818. View

Li Y, Li Y, Xu S, Chen Y, Zhou P, Hu T . N-Acylethanolamine acid amidase (NAAA) exacerbates psoriasis inflammation by enhancing dendritic cell (DCs) maturation. Pharmacol Res. 2022; 185:106491. DOI: 10.1016/j.phrs.2022.106491. View

Xu Y, Lan P, Wang T . The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Medicina (Kaunas). 2023; 59(11). PMC: 10672798. DOI: 10.3390/medicina59111984. View

Li S, Yang Y, Zheng H, Zheng Y, He C, Lai B . Introduction of oxygen vacancy to manganese ferrite by Co substitution for enhanced peracetic acid activation and O dominated tetracycline hydrochloride degradation under microwave irradiation. Water Res. 2022; 225:119176. DOI: 10.1016/j.watres.2022.119176. View

Li Z, Zhao Y, Huang H, Zhang C, Liu H, Wang Z . A Nanozyme-Immobilized Hydrogel with Endogenous ROS-Scavenging and Oxygen Generation Abilities for Significantly Promoting Oxidative Diabetic Wound Healing. Adv Healthc Mater. 2022; 11(22):e2201524. DOI: 10.1002/adhm.202201524. View

10.

Byrne A, Maher T, Lloyd C . Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?. Trends Mol Med. 2016; 22(4):303-316. DOI: 10.1016/j.molmed.2016.02.004. View

11.

Shahabi R, Anissian A, Javadmoosavi S, Nasirinezhad F . Protective and anti-inflammatory effect of selenium nano-particles against bleomycin-induced pulmonary injury in male rats. Drug Chem Toxicol. 2019; 44(1):92-100. DOI: 10.1080/01480545.2018.1560466. View

12.

Liu Q, Ren Y, Jia H, Yuan H, Tong Y, Kotha S . Vanadium Carbide Nanosheets with Broad-Spectrum Antioxidant Activity for Pulmonary Fibrosis Therapy. ACS Nano. 2023; 17(22):22527-22538. DOI: 10.1021/acsnano.3c06105. View

13.

Zhuo S, Fang J, Zhu C, Du J . Preparation of palladium/carbon dot composites as efficient peroxidase mimics for HO and glucose assay. Anal Bioanal Chem. 2019; 412(4):963-972. DOI: 10.1007/s00216-019-02320-0. View

14.

Malaviya R, Laskin J, Laskin D . Anti-TNFα therapy in inflammatory lung diseases. Pharmacol Ther. 2017; 180:90-98. PMC: 5693260. DOI: 10.1016/j.pharmthera.2017.06.008. View

15.

Karampitsakos T, Juan-Guardela B, Tzouvelekis A, Herazo-Maya J . Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023; 95:104766. PMC: 10469771. DOI: 10.1016/j.ebiom.2023.104766. View

16.

Plikus M, Wang X, Sinha S, Forte E, Thompson S, Herzog E . Fibroblasts: Origins, definitions, and functions in health and disease. Cell. 2021; 184(15):3852-3872. PMC: 8566693. DOI: 10.1016/j.cell.2021.06.024. View

17.

Mahalanobish S, Saha S, Dutta S, Sil P . Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis. Pharmacol Res. 2019; 152:104591. DOI: 10.1016/j.phrs.2019.104591. View

18.

Li M, Tan L, Tang L, Li A, Hu J . Hydrosoluble 50% N-acetylation-thiolated chitosan complex with cobalt as a pH-responsive renal fibrosis targeting drugs. J Biomater Sci Polym Ed. 2016; 27(10):972-85. DOI: 10.1080/09205063.2016.1175405. View

19.

Dos Santos Haupenthal D, Mendes C, Silveira G, Zaccaron R, Correa M, Nesi R . Effects of treatment with gold nanoparticles in a model of acute pulmonary inflammation induced by lipopolysaccharide. J Biomed Mater Res A. 2019; 108(1):103-115. DOI: 10.1002/jbm.a.36796. View

20.

Estornut C, Milara J, Bayarri M, Belhadj N, Cortijo J . Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022; 12:794997. PMC: 8815729. DOI: 10.3389/fphar.2021.794997. View